Abstract
BackgroundEGFR is a promising therapeutic target expressed on multiple tumor cell types. While single-targeting antibodies and ADCs have been explored, limitations encountered with current therapies, such as drug resistance and...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
